{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:57Z","timestamp":1791976137113,"version":"4.4.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/cad.0b013e328352a8fe","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T04:44:54Z","timestamp":1331786694000},"page":"754-757","source":"Crossref","is-referenced-by-count":55,"title":["A dramatic fetal outcome following transplacental transfer of dasatinib"],"prefix":"10.1097","volume":"23","author":[{"given":"Paul","family":"Berveiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Anselem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Delezoide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Sauvageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Tsatsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210227","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia.","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"R2-13-20210227","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"R4-13-20210227","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome.","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-13-20210227","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome.","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"R6-13-20210227","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3816\/CLM.2009.n.064","article-title":"Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.","volume":"9","author":"Cole","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"R8-13-20210227","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1124\/dmd.108.022764","article-title":"Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.","volume":"36","author":"He","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R9-13-20210227","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3109\/10428194.2010.497982","article-title":"Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.","volume":"51","author":"Kroll","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R12-13-20210227","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-8722-2-42","article-title":"Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study.","volume":"2","author":"Conchon","year":"2009","journal-title":"J Hematol Oncol"},{"key":"R13-13-20210227","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"R14-13-20210227","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"OHare","year":"2005","journal-title":"Cancer Res"},{"key":"R15-13-20210227","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e328352a8fe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:35:50Z","timestamp":1786048550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201208000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328352a8fe","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}